KR100680134B1 - Injectable filler made by acellular dermis - Google Patents

Abstract

The present invention relates to a filler processed into a cell-like dermis into an injectable form, and in particular, a filler having a width of 1.5 mm to 2.3 mm, a length of 4 mm to 8 mm, and a streamlined filler.

The streamlined filler particles can easily pass through the needle to increase the accuracy of the procedure by lowering the injection pressure during injection.The width of the filler particles in the range of 1.5 mm to 2.3 mm allows the filler particles to be injected 16 or 18 gauge one by one. By passing the needle to uniformly expand the volume, as well as to improve the efficiency of the volume expansion, the length is included in the range of 4mm to 8mm has an effect that can naturally respond to the movement of the facial muscles.

Cell free dermis, filler, streamline, syringe, wrinkle removal, facial contour

Description

Filler processed into cell-like dermis into injectable form {INJECTABLE FILLER MADE BY ACELLULAR DERMIS}

BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 shows filler particles obtained by cutting 2 mm × 2 mm of shroud or alloderm, which is a kind of cell-free dermis.

Figure 2 shows the filler particles cut into a streamlined, especially almond-shaped aloderum or shredder which is a kind of acellular dermis as an embodiment according to the present invention.

Figure 3 shows the filler particles cut into a streamlined, particularly elongated hexagonal shape of aloderum or shredder which is a kind of acellular dermis as an embodiment according to the present invention.

Figure 4 shows the filler particles cut to add a rod-shaped piece on either side as a streamlined, particularly elongated octagonal shape of a cell-like dermis, an aloder or shredder, as an embodiment according to the present invention.

FIG. 5 is a view illustrating a procedure of treating a facial part using the filler illustrated in FIG. 2.

6 is a view for explaining the relationship between the width of the filler particles injected into the subcutaneous fat layer and skin volume expansion.

Fig. 7 shows how filler particles are arranged in a constant direction, i.e., the surface is upward.

8 shows the surface, the back and the sides of the filler particles evenly arranged.

9A and 9B show a filler according to the present invention injected into the dermal portion of a rat, and after 6 weeks, the portion is stained with hematoxylin-eosin staining (HE stain), followed by transmission electron microscopy (Transmission Electron Microscope). Taken with).

Figure 10a and Figure 10b is a photo of the filler in accordance with the present invention injected into the dermal portion of the rat, 13 weeks after the portion was stained with hematoxylin-eosin staining method (H-E stain) photograph taken by TEM.

Figure 11 is injected into the dermal portion of the experimental rat filler, and after 32 weeks the portion was stained by hematoxylin-eosin staining (H-E stain) photograph taken by TEM.

12a and 12b is a state in which fibroblasts are generated between the injected filler particles of the present invention, and collagen fibers newly produced by the injected collagen fibers and the fibroblasts of the present invention by TEM.

The present invention relates to a filler used for wrinkle removal and facial contour correction using acellular dermis, and more particularly, to the shape of a filler. Fillers are implants used to improve wrinkles or to reconstruct facial contours by inserting them into specific areas to expand soft tissue, and generally use biological tissue or chemicals.

Fillers made of chemicals such as polyacrylamide or polyethylene do not cause allergic reactions by foreign proteins in the human body, but they can be used as permanent fillers because they are not absorbed by the body over time, but they are easy to remove once injected. Because it causes invasion of surrounding tissues, care must be taken during the procedure, and if it is injected incorrectly, recovery is difficult.

On the other hand, the filler composed of the patient's own biological tissues, such as autologous fat, collagen is a biological tissue separated from the patient's human body does not cause an allergic reaction after injection. However, in order to use this method, there is a disadvantage that a separate process of extracting a living tissue before the procedure is inevitable.

Therefore, in recent years, cell-free dermal fillers, such as alloderm and shurederm, which have been immunized with the dermis separated from the carcass, have been developed and utilized in the field of plastic surgery.

Acellular dermis is a substance made by removing the epidermal layer and immune cells from human skin. Since it is composed of non-immune tissues and fibers, that is, collagen fibers, there are no side effects such as immune rejection or infection.

It was developed in the United States for the treatment of burns in 1991, but it has been widely used in shaping such as wrinkle removal, rhinoplasty and scar removal. When the cell-free dermis is implanted into the skin, new cells, ie, fibroblasts, enter and grow, while new blood vessels form and new collagen fibers are produced by infiltrating fibroblasts. Undergoes the process of being removed.

Since the cell-free dermis is absorbed into the body after a certain period of time after skin transplantation, there is no difficulty in elimination, which is a disadvantage of the chemical filler, but it is absorbed into the body as time passes and the procedure must be performed again when the volume sense disappears. This remains.

The procedure for inserting acellular dermis into soft tissues to be expanded such as wrinkles or facial contours can be classified into two types. One is to cut the skin through a surgical operation and insert the acellular dermis in the form of a stripe (plate or layered or rolled) into the incision. It is processed and injected.

Surgical procedures have the disadvantages of a large surgical incision because of the wide incision site, and a long recovery time such as treatment of edema occurring after surgery. In addition, the cell-shaped dermis in the form of a strip embedded in the skin has a disadvantage in that the movement is not natural in appearance because it moves as a plate as a separate tissue from the patient's skin until engraftment on the skin of the patient.

The injection method using a syringe is to inject the cell-free dermis powdered in a size of about 1200 μm with the saline solution to the treatment site. This procedure has the advantage that the procedure is simple and quick to recover because it does not cut the skin, but the problem is that the duration is very short, about 10 weeks.

In other words, by processing the cell-free dermis into fine grains, the injection is possible, and the procedure is easy, but the particles are fine and the surface area is wide, so that the infiltration of immune cells and macrophages is shortened and the period of absorption into the body is shortened. The short duration problem not only creates the hassle of having to repeat the procedure for a short period of time in order to maintain the effectiveness of the procedure, but also makes it difficult to use the procedure due to the high cost of using the cell-free dermis. have. In addition, in the case of powder-processed cell-free dermis, there is a problem that the skin feel at the injection site is harder than normal skin because of the rapid fibroblast infiltration occurs.

As described above, the filler has various problems such as allergic reaction by foreign protein, simplicity of procedure and persistence of effect, and especially in wrinkle removal using acellular dermis, the simplicity of procedure and the persistence of procedure effect It has been known to be incompatible conditions.

Recognizing this problem, as shown in FIG. 1, aloderm, which is a kind of cell-free dermis, is processed into 2mm × 2mm particles and then injected using a 16 or 18 gauge syringe to inject a cell-shaped dermis into stripe form. It has been reported in the academic community that the effect of the procedure can last for many years, similar to the insertion of the. In other words, by simply using a syringe, the particle size of the filler is increased, delaying angiogenesis and macrophages, delaying fibroblast substitution, and extending the duration, thereby providing new electricity in the field of apoptotic dermis. It became.

For reference, the reason for using a 16 or 18 gauge needle during the procedure is as follows. Generally, since the skin thickness of the face is about 1 mm, when the acellular dermis is injected subcutaneously using a thicker needle, the acellular dermal layer to be injected is formed relatively thicker than the skin. It may not be smooth and bumpy. In addition, the swelling area is easy to occur after the procedure is large, and the injection site is visually discernible, which may cause undesirable results.

On the other hand, when the procedure using a needle that is thinner than 16 or 18 gauge, there is a problem that the efficiency of volume expansion is inferior. For this reason, it is preferable to use 16 or 18 gauge needles when injecting filler into the facial area.

However, when filler particles are processed into a square shape (2 mm x 2 mm) and injected, it is not easy to pass through a 16 or 18 gauge needle, so the injection pressure is high. If the injection pressure is higher than a certain threshold (injection needle pressure: 0.41 kgf / cm 2), it is difficult to precisely control the injection amount of the filler, and as a result, it becomes a factor that makes the procedure difficult.

In addition, when the length of the filler is short, such as about 2 mm, it was confirmed that the efficiency of the volume expansion is inferior.

SUMMARY OF THE INVENTION An object of the present invention is to provide a filler having a shape that allows an injection pressure to a degree that can precisely control the injection amount by improving the above-described problem.

In addition, an object of the present invention is to enable the filler particles to pass through the 16 gauge or 18 gauge needle one by one, thereby allowing the volume to be uniformly expanded.

In addition, an object of the present invention is to provide a filler having a shape capable of improving the efficiency of volume expansion due to filler injection.

Another object of the present invention is to provide a filler in which the surface, the back, and the sides of the cell-free dermis are evenly mixed when the filler is made of the cell-free dermis.

In addition, an object of the present invention is to provide a filler having a shape such that the facial movement is naturally maintained after the filler is injected into the engraftment.

It is also an object of the present invention to provide a filler in which the filler is mixed with the fibrin and injected to further delay the absorption of the filler into the living body, thereby increasing the duration.

In order to achieve the above object, the present invention provides a streamlined filler having a width in the range of 1.5 mm to 2.3 mm and a length in the range of 4 mm to 8 mm. 2 to 4 illustrate an embodiment of a filler processed into a shredder or alloder, which is a kind of acellular dermis, in the above-described shape, and FIG. 5 illustrates a procedure of using the filler shown in FIG. 2. 6 is a view illustrating the extent of volume expansion according to the width of the filler when the filler is injected into the subcutaneous fat layer, and FIG. 7 shows a state in which the filler particles are uniformly arranged upwards. 8 shows a state in which the surface, the back side, and the side surfaces of the filler particles are evenly arranged. Hereinafter, the present invention will be described in detail with reference to FIGS. 2 to 8.

Cell-free dermis, as mentioned above, removes the epidermal layer and immune cells from the skin isolated from the corpse, which is somewhat different depending on the site, but is generally about 1 mm thick, 2 cm x 7 cm or 3 cm Size products, such as x 7 cm, are commercially available. In Fig. 2, for example, shredders having a size of 2 cm by 7 cm are shown, and a filler patterned into streamlined particles having a width of 1.5 mm to 2.3 mm and a length of 4 mm to 8 mm, in particular almond-shaped particles, is characterized as a characteristic configuration. I'm proposing. At this time, the filler may be further extended from both ends of the almond-shaped as shown in Figure 2, the narrower the width as it proceeds in the longitudinal direction, it may have a pointed attachment. By forming it with such an attachment, the loss at the time of patterning acellular dermis can be minimized.

On the other hand, Figure 3 is proposed as a characteristic configuration of a filler patterned in an elongated hexagonal shape as a streamlined particle of the size, Figure 4 is a bar-shaped extension to the both ends of the longitudinal direction of the elongated octagonal as streamlined particles of the size In addition, the patterned filler is proposed as a characteristic structure.

Generally, the patterned filler is injected into the subcutaneous fat layer through a syringe after a period of hydration treatment. In this case, sufficient hydration time is required, and the infusion pressure can be lowered by maintaining the inherent viscosity of the skin. Therefore, it is easy to control the injection amount of the filler during the procedure, and since the filler is softened, the overlap of the filler particles is achieved without dead space.

Applicant set the hydration time to 20 minutes in consideration of the degree of volume expansion after the procedure and experimented with fillers patterned in various shapes. As a result, it was confirmed that the filler of the above-mentioned shape exerts an excellent effect in wrinkle treatment or facial contour correction.

First, the relationship between the width of the filler and the injection pressure during the filler injection is as follows. By subdividing the movement of the filler through the syringe, it can be divided into the stage where the filler just enters the syringe opening and the stage passes through the syringe. The injection pressure at the stage where the filler just enters the syringe opening is higher than the injection pressure at the stage where the filler flows through the syringe. Therefore, when the filler is injected into the syringe, the pressure felt in the hand is not constant, and as the filler is injected into the needle one by one, clogging and passing are felt repeatedly.

By the way, when the width of the filler becomes 2.3 mm or more, the pressure passing through the 16 gauge injection needle becomes 0.41 kgf / cm 2 or more, and at this time, the pressure difference between clogging and passage felt by the hand becomes very large. Therefore, it is impossible to uniformly control the injection amount of the filler. In other words, the injection amount of the filler cannot be uniformly controlled because the pressure applied to the hand cannot be appropriately attenuated when the transition from the clogging step to the passage step is performed.

In addition, at such pressure, when one filler is ejected from the needle at a high speed, it also adversely affects the distribution and shape of other fillers that are already injected, causing the fillers to be unevenly distributed and agglomerate with each other. .

However, when the width of the filler is 2.3 mm or less, since the pressure difference in the blockage and passage stage is not large, relatively uniform control is possible. Therefore, it is preferable that the width of a filler becomes 2.3 mm or less.

On the other hand, the width of the filler is 2.3 mm or less, and the injection pressure is not necessarily 0.41 kgf / cm 2 or less. The injection pressure may vary depending on the shape of the filler particles. For example, even if the width is 2 mm, if the filler is rectangular in shape, the injection pressure exceeds 0.41 kgf / cm 2 and is not suitable for the procedure. For this reason, the present invention proposes to process the filler particles in a streamlined fashion. Applicant was able to increase the accuracy of the procedure by significantly lowering the injection pressure by processing the filler in a streamlined injection.

Here, the streamline refers to a form in which both ends of the filler particles have a narrow width and a wide center portion thereof. Both ends are tapered to facilitate the passage of the injection needle, and the center portion is wider to effectively expand the volume of the soft tissue. This will be described later in detail.

In particular, by patterning the filler into the almond shape as shown in FIG. 2, the loss when patterning the cell free dermis can be minimized. In addition, as shown in FIG. 2, the filler is further extended from both ends of the almond shape, and the width thereof becomes narrower as it proceeds in the longitudinal direction, and the loss at the time of patterning the cell-free dermis can be further reduced by having a pointed attachment. have. Minimizing the loss in the procedure using expensive cell-free dermis means that the volume can be expanded even more at the same cost, thereby reducing the cost of the procedure.

Next, the relationship between the width | variety and the volume expandability of a filler particle is demonstrated with reference to FIG. 5 and FIG. The filler is injected into the subcutaneous fat layer through a 16 gauge needle, as shown in FIG. 5. First, the needle is inserted into the subcutaneous fat layer to form a filler injection space, and then the needle is retracted while injecting the filler by applying pressure to the syringe.

Although there is a difference depending on the treatment site, a filler injection space is generally formed at intervals of about 7 mm at the treatment site. For example, three lines are formed as injection spaces in FIG. 5. When forming the injection space, it is not necessary to insert a needle into each line. Insert the injection needle in a spaced distance from the treatment site and adjust the angle of the needle while considering the skin elasticity to form a filler injection space by inserting the injection needle in each line. Therefore, only 1 needle mark appeared on the outside.

At this time, since the diameter of the 16 gauge needle is 1.295 mm (16 gauge), the filler injection space formed by the needle becomes about 1.295 mm in diameter. Therefore, the filler particles having a larger width are bulged in a direction perpendicular to the skin by the pressing force from both sides of the injection space as shown in FIG. 6. By bulging in this way, the volume of the facial skin is expanded in the vertical direction. (The thickness of the filler particles is limited to 1 mm as described above.)

Therefore, the larger the width of the filler particles, the greater the effect of volume expansion. However, since the thickness of the facial skin is about 1 mm, injecting an excessively large filler may result in aesthetically undesirable results such as uneven surface. Accordingly, the present invention proposes a width of the filler to prevent the surface from becoming excessively uneven in consideration of the facial skin thickness, and the value thereof is 2.3 mm or less.

On the other hand, when the width of the filler particles is 1.5 mm or less, the width of the filler particles and the diameter of the injection space of the subcutaneous fat layer into which the filler particles are injected are not significantly different. Therefore, the force of the filler particles injected into the subcutaneous fat layer from the side of the injection space is small, and as a result, the degree of swelling in the direction perpendicular to the skin is small. Therefore, it is difficult to expect the effect of filler injection.

In addition, when the width of the filler particles is 1.5 mm or less, there is a risk that two filler particles are caught at once in a 16 gauge or 18 gauge needle, and in this case, the filler particles cannot pass through the needle and the procedure is impossible. For this reason, the width of the filler particles is preferably included in the range of 1.5 mm to 2.3 mm.

Next, the relationship between the width of the filler particles and the arrangement of the filler particles will be described with reference to FIGS. 7 and 8. In filler injection, the filler particles are arranged partially out of the injection needle one by one. On the other hand, the cell-free dermis shows a minute difference in the process of engraftment in the human body according to its surface, back and side.

In view of such a difference in engraftment process, as shown in FIG. 7, the filler particles are arranged with the surface of the cell free dermis aligned all up so that the surface of the cell free dermis can contact skin cells. It is good.

However, such control during filler injection is impossible, and as shown in FIG. 8, it is suboptimal to randomly mix the surfaces, the back, and the sides of the cell-free dermis into contact with the skin.

However, when the width of the filler particles is larger than 2.3 mm, the possibility that the side surfaces of the filler particles come into contact with the skin is very low. This is closely related to the thickness of the filler particles of about 1 mm. Since the thickness of the filler particles is about 1 mm and thinner than the width, when the width of the particles is larger than 2.3 mm, the filler particles are difficult to stand laterally and are inclined. As a result, the filler particles collapse and the surface or back face contacts the skin. That is, the possibility that the side surface of a filler particle comes in contact with skin becomes low.

Therefore, the surface, back and sides of the filler particles may not evenly contact the skin, which lowers the engraftment rate of the filler. Therefore, the width of the filler particles is preferably kept at 2.3 mm or less.

Next, the length of the filler particles, the naturalness of facial movement and the efficiency of the procedure will be described. If the length of the filler particles is larger than 8 mm, the facial movement becomes unnatural. Filler particles injected into the subcutaneous fat layer move like a plate. Each particle is arranged partially overlapping with each other, and the overlapping parts become joints and move naturally organically.

However, when the filler particles are larger than 8 mm in length, the size of the plate mentioned above becomes too large and does not naturally form as the facial muscles move. Therefore, it is preferable to maintain the length of the filler particles to 8 mm or less for naturalness. On the other hand, if the length of the filler particles is 4 mm or less, the procedure is cumbersome and the efficiency of volume expansion is lowered.

The present invention as described above can be applied throughout facial contour molding using a filler. In other words, it can be used for facial contouring using fillers such as ears, under cheeks, cheekbones, temples, nose, lips, jawline, and forehead.In addition, depending on the injection layer, the skin, subcutaneous layer, muscle layer, and periosteum can be used. It is a very efficient method for facial contour correction because it can be variously selected to adjust the volume increase naturally and appropriately, and the position and amount of injection of the filler are variable according to each treatment site, but the shape of the filler particles, which is the technical idea of the present invention The same applies to the size and size.

For example, it is preferable to use an 18 gauge needle because the skin is thinner than other parts of the face, and a filler particle having a width of about 1.5 mm and a length of about 4 mm is used. This range is included in the width and length range of the filler particles proposed by the present invention.

Next, an embodiment in which the filler of the shape according to the present invention is mixed with fibrin in order to further increase the duration will be described. First, 10 cc of blood is collected, anticoagulant is added to the collected blood, and centrifuged for 10 minutes. Only plasma components are taken from the centrifuged blood and thromboxane is added to form fibrin. Mix the acellular dermis or fascia and fibrin of the shape and size according to the present invention described above and inject it into the treatment site.

Using a fibrin-mixed filler in this way, the mesh foam of fibrin defends the recollagement of the cell-free dermis (allodum, shredder) or fascia, delaying the time it is absorbed in vivo. Thus, increasing the duration.

Hereinafter, with reference to FIGS. 9 to 12, after the filler according to the present invention is injected into the sub-dermal portion of the experimental rat, a change in the filler appearing over time will be described. At this time, the size of the injected filler is 1.8 mm x 4 mm.

9A and 9B show a filler according to the present invention injected into the dermal portion of a rat, and after 6 weeks, the portion is stained with hematoxylin-eosin staining (HE stain), followed by transmission electron microscopy (Transmission Electron Microscope). (Hereinafter referred to as 'TEM').

FIG. 9A is a photograph of the epidermis, muscle, and injected filler beneath the experimental rat, and FIG. 9B is an enlarged view of the boundary region in FIG. 9A. 9A and 9B, it can be seen that darker red portions are scattered around the outer periphery of the injected filler particles than other portions of the filler particles. These dark red areas are collagen fibers newly produced by the infiltration of fibroblasts, and it can be seen that the infiltration of fibroblasts into the injected filler originates from the periphery of the filler particles.

When filler is injected, fibroblasts infiltrate first at the injection site. Subsequently, when the fibroblasts infiltrate to some extent, new collagen fibers are generated by the fibroblasts, while collagen fibers of the injected filler are removed from the periphery by the macrophages to replace the collagen fibers.

Since the infiltration of fibroblasts occurs at the boundary of the filler particles, the filler according to the present invention having a larger particle size has an effect of delaying the infiltration of fibroblasts than the powdered filler, and also the powder processed Since the surface area is smaller than that of the filler, the replacement of collagen fibers is also slow.

Collagen fibers produced by fibroblasts have a firm skin feel, such as scars, rather than the elasticity of normal skin because they are smaller and denser than normal skin. Therefore, in the case of using the filler of the present invention, as described above, the fibroblasts are infiltrated more slowly than the powder-treated fillers, and thus, the replacement of the collagen fibers newly generated by the fibroblasts is also slow. While maintaining a natural skin feel.

10a and 10b is a picture taken by TEM after injecting the filler according to the present invention into the dermal portion of the experimental rat, 13 weeks after the portion was stained by hematoxylin-eosin staining (H-E stain) method.

FIG. 10A is a photograph of the epidermis, muscle, and injected filler beneath the experimental rat, and FIG. 10B is an enlarged view of the boundary region in FIG. 10A. In FIGS. 9A and 9B, the darker red portion than the other sites at the periphery of the injected filler particles is collagen fibers newly produced by infiltration of fibroblasts, as in FIGS. 9A and 9B.

10A and 10B, it can be seen that the infiltration of fibroblasts into the injected filler particles and the replacement with new collagen fibers produced by the fibroblasts are further advanced compared to FIGS. 9A and 9B.

FIG. 11 is a photograph taken by TEM after injecting a filler according to the present invention into the dermal portion of a rat, and staining the portion by hematoxylin-eosin staining (HE stain) after 32 weeks. An enlarged image of the border of the epidermis, muscle and injected filler beneath it. In FIG. 11, the darker red portion than the other sites in the injected filler particles are collagen fibers newly produced by infiltration of fibroblasts as in FIGS. 9A and 9B.

Referring to FIG. 11, infiltration of fibroblasts starting from the periphery of the injected filler particles and replacement with new collagen fibers proceeded to the inner center of the filler particles as compared to FIGS. 10A and 10B. However, it can be seen that a significant part of the injected filler particles still retains their shape.

Conventionally, when the filler was powder-injected and injected, the duration of soft tissue expansion was about 10 weeks at most. On the other hand, in the case of the filler having the shape and size according to the present invention, as described above with reference to FIGS. 9A to 11, a large portion of the filler is still maintained even after 32 weeks after the filler injection, and thus the expanded state is continuously Was being maintained.

Therefore, it can be seen that the filler having the shape and size of the present invention has a significantly longer persistence of soft tissue expansion than conventional powder processing. This is because the infiltration of fibroblasts into the injected filler starts with the periphery of the injected filler particles, as described in Figures 9a and 9b, in the case of the filler having the shape and size of the present invention than the powder form of a wide surface area This is because the macrophages and the replacement with new collagen fibers is much slower.

In particular, considering that the growth rate of the experimental rats is 20 times that of humans, 32 weeks in the experimental rats correspond to approximately 10 years of human, and therefore, theoretically, the effect of soft tissue expansion by the filler of the present invention. Can be maintained for up to 10 years.

Next, the collagen fibers of the filler particles according to the present invention and the fillers according to the present invention will be described with reference to FIGS. 12A and 12B, and the collagen fibers newly generated by the infiltration of fibroblasts.

12A is a TEM photograph of the state in which fibroblasts are generated between the injected filler particles of the present invention, and FIG. 12B shows the infiltration of fibroblasts into the injected filler particles and the replacement by the newly produced collagen fibers. As time progressed, the collagen fibers of the injected filler particles and the collagen fibers newly generated by the fibroblasts were taken by TEM.

12a, it can be seen that fibroblasts are generated between the injected filler particles, and also that new collagen fibers generated from the fibroblasts begin to penetrate and replace from the periphery of the injected filler particles.

On the other hand, it can be seen from Fig. 12b that the collagen fibers of the injected filler particles remain relatively sparsely at regular intervals, while the tissue of the collagen fibers newly produced by the fibroblasts is small and dense.

Collagen fibers newly produced by these fibroblasts show a firm skin feel like the skin of scars rather than the elasticity of normal skin. Therefore, the faster the replacement of newly produced collagen fibers, the more natural skin feel will be. I can't keep it.

Therefore, in the case of the shape and size of the filler according to the present invention, since the replacement of collagen fibers by the fibroblasts proceeds gradually from the periphery of the injected filler particles, the natural skin feel of normal skin compared to the filler that is powder processed and injected It can be maintained for a long time.

The present invention is not limited to the examples described above, and the rights of the present invention are determined as described in the appended claims. In addition, various modifications of the present invention can be carried out by those skilled in the art, but it is obvious that all belong to the scope of the present invention.

As examined above, according to the shape of the filler particle provided by this invention, the injection amount of a filler can be precisely controlled and there exists an effect which can improve the accuracy of a procedure.

In addition, there is an effect to increase the efficiency of the volume expansion during the procedure to achieve a more satisfactory procedure.

In addition, by injecting a filler consisting of acellular dermis, the surface, back and sides of the acellular dermis can be evenly mixed, thereby increasing the engraftment rate of the filler.

In addition, by injecting the filler so that the appearance of the facial movements naturally until engraftment, there is an effect to further increase the satisfaction of the procedure.

Claims (7)

In a filler processed into a cell-like dermis in the form of particles to be injectable in a 16 gauge or 18 gauge needle, The filler has a streamlined shape in which both ends in the longitudinal direction of the particle are narrow in width and wide in the center. The center of the filler particles is a filler, characterized in that the range of 1.5 mm to 2.3 mm. The method of claim 1, The filler particles are characterized in that the length of the range of 4 mm to 8 mm. delete The method according to claim 1 or 2, The filler particles are characterized in that the width of both ends in the longitudinal direction toward the end gradually narrower and pointed. The method according to claim 1 or 2, The filler particles are characterized in that the elongated hexagonal shape. The method according to claim 1 or 2, The filler particles have an elongated octagonal shape, and a filler having thin rod-shaped extensions is added to both ends in the longitudinal direction. The method according to claim 1 or 2, Filler, characterized in that the filler is mixed with fibrin.

Images